Jump to Main Contents
研究所ロゴ

Home > Organization > Fundamental Innovative Oncology Core > Drug Development and Disease Model Core > Department of Biomarkers for Early Detection of Cancer > Research Papers

Research Papers

2021

  1. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Ito M, Chen W Y, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayaka N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biol, 2021. in press PMID: DOI: 10.1016/j.redox.2021.101926

  2. Meng X, Mori T, Matsumoto F, Miura N, Onidani K, Kobayashi K, Matsuzaki Y, Yoshimoto S, Ikeda K, Honda K. Hepatitis B X-interacting protein, involved in increasing proliferation and cell migration, is a prognostic marker in head and neck squamous cell carcinoma. Oral Sci Int, 2021. in print

  3. Meng X, Matsumoto F, Mori T, Miura N, Ino Y, Onidani K, Kobayashi K, Matsuzaki Y, Yoshimoto S, Ikeda K, Honda K. BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Anticancer Res, 2021. 41(2): 1089-1099 PMID: 33517320 DOI: 10.21873/anticanres.14867

2020

  1. Sato Y, Kobayashi T, Nishiumi S, Okada A, Fujita T, Sanuki T, Kobayashi M, Asahara M, Adachi M, Sakai A, Shiomi H, Masuda A, Yoshida M, Takeuchi K, Kodama Y, Kutsumi H, Nagashima K and Honda K. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. Cancers, 2020. 12(9): E2625 PMID: 32937962 DOI: 10.3390/cancers12092625
  2. Yokose T, Kabe Y, Matsuda A, Kitago M, Matsuda S, Hirai M, Nakagawa T, Masugi Y, Hishiki T, Nakamura Y, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Honda K, Kashiro A, Morizane C, Nara S, Kikuchi S, Shibahara T, Itonaga M, Ono M, Minegishi N, Koshiba S, Yamamoto M, Kuno A, Handa H, Sakamoto M, Suematsu M and Kitagawa Y. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Cancers, 2020. 12(9): E2469 PMID: 32878320 DOI: 10.3390/cancers12092469
  3. Kihara T, Yamagishi K, Honda K, Ikeda A, Yatsuya H, Saito I, Kokubo Y, Yamaji T, Shimazu T, Sawada N, Iwasaki M, Iso H and Tsugane S; JPHC Study Group. Apolipoprotein A2 Isoforms in Relation to the Risk of Myocardial Infarction: A Nested Case-Control Analysis in the JPHC Study. J Atheroscler Thromb, 2020. Online ahead of print.  PMID: 32863295 DOI: 10.5551/jat.56218
  4. Kato S and Honda K. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers, 2020. 12(7): E1965. PMID: 32707720 DOI: 10.3390/cancers12071965
  5. Aoki M, Shoji H, Kashiro A, Takeuchi K, Shimizu Y and Honda K. Prospects for Comprehensive Analyses of Circulating Tumor Cells in Tumor Biology. Cancers, 2020. 12(5): E1135. PMID: 32369927 DOI: 10.3390/cancers12051135
  6. Sugano T, Yoshida M, Masuda M, Ono M, Tamura K, Kinoshita T, Tsuda H, Honda K, Gemma A and Yamada T. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. Br J Cancer, 2020. 122(12):1811-1817. PMID: 32265507 DOI: 10.1038/s41416-020-0821-y
  7. Sakamoto S, Komatsu T, Watanabe R, Zhang Y, Inoue T, Kawaguchi M, Nakagawa H, Ueno T , Okusaka T, Honda K, Noji H, Urano Y. Multiplexed single-molecule enzyme activity analysis for counting disease-related proteins in biological samples. Science Adv, 2020. 6(11): eaay0888. PMID: 32195342 DOI: 10.1126/sciadv.aay0888
  8. Xu X, Honda K, Miura N, Hori S, Blanc SL, Bergmann F, Gaida MM, Volkmar M, Schimmack S, Hackert T, Strobel O and Felix K. Actinin-4 splice variant – a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplams. J Cancer, 2020. 11(8): 2318-2328. PMID: 32127958 DOI: 10.7150/jca.37503
  9. Abe Y, Hirano H, Shoji H, Tada A, Isoyama J, Kakudo A, Gunji D, Honda K, Boku N, Adachi J and Tomonaga T. Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens. Theranostics, 2020. 10(5): 2115-2129. PMID: 32089736 DOI: 10.7150/thno.37623

2019

  1. Kato S and Honda K. CA19-9 as a therapeutic target in pancreatitis. Ann Transl Med, 2019. 7(Suppl 8): S318. PMID: 32016036 DOI: 10.21037/atm.2019.09.161
  2. Nambu M, Masuda T, Ito S, Kato K, Kojima T, Daiko H, Ito Y, Honda K and Ohtsuki S. Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer. Biol Pharm Bull, 2019. 42(10): 1766-1771. PMID: 31582665 DOI: 10.1248/bpb.b19-00395
  3. Suzuki T, Yamazaki H, Honda K, Ryo E, Kaneko A, Ota Y and Mori T. Altered DNA methylation is associated with aberrant stemness gene expression in earlystage HNSCC. Int J Oncol, 2019. 55(4): 915-924. PMID: 31432153 DOI: 10.3892/ijo.2019.4857
  4. Onidani K, Shoji H, Kakizaki T, Yoshimoto S, Okaya S, Miura N, Sekikawa S, Furuta K, Lim CT, Shibahara T, Boku N, Kato K and Honda K. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. Cancer Sci, 2019. 110(8): 2590-2599. PMID: 31169336  DOI: 10.1111/cas.14092
  5. Kobayashi T and Honda K. Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies. Expert Rev Mol Diagn, 2019. 19(8):651-654. PMID: 31298060 DOI: 10.1080/14737159.2019.1643718
  6. Iemoto T, Nishiumi S, Kobayashi T, Fujigaki S, Hamaguchi T, Kato K, Shoji H, Matsumura Y, Honda K and Yoshida M. Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncol Lett, 2019. 17(1): 831-842. PMID: 30655836 DOI: 10.3892/ol.2018.9731
  7. Nishiumi S, Fujigaki S, Kobayashi T, Kojima T, Ito Y, Daiko H, Kato K, Shoji H, Kodama Y, Honda K and Yoshida M. Metabolomics-based Discovery of Serum Biomarkers to Predict the Side-effects of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Anticancer Res, 2019. 39(1): 519-526. PMID: 30591504 DOI: 10.21873/anticanres.13143
  8. Abouleila Y, Onidani K, Ali A, Shoji H, Kawai T, Lim CT, Kumar V, Okaya S, Kato K, Hiyama E, Yanagida T, Masujima T, Shimizu Y and Honda K. Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells. Cancer Sci, 2019. 110(2):697-706. PMID: 30549153 DOI: 10.1111/cas.13915
  9. Honda K, Katzke VA, Husing A, Okaya S, Shoji H, Onidani K, Olsen A, Tjonneland A, Overvad K, Weiderpass E, Vineis P, Muller D, Tsilidis KK, Palli D, Pala V, Tumino R, Naccarati A, Panico S, Aleksandrova K, Boeing H, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Lagiou P, Khaw KT, Wareham NJ, Travis RC, Merino S, Duell EJ, Rodriguez-Barranco M, Chirlaque MD, Barricarte A, Rebours V, Boutron-Ruault MC, Romana Mancini F, Brennan P, Scelo G, Manjer J, Sund M, Ohlund D, Canzian F and Kaaks R. CA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation. Int J Cancer, 2019. 144(8):1877-1887. PMID: 30259989 DOI: 10.1002/ijc.31900

2018

  1. Fujigaki S, Nishiumi S, Kobayashi T, Suzuki M, Iemoto T, Kojima T, Ito Y, Daiko H, Kato K, Shouji H, Honda K, Azuma T and Yoshida M. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomark Med, 2018. 12(8): 827-840. PMID: 30043633 DOI: 10.2217/bmm-2017-0449
  2. Kobayashi T, Sato Y, Nishiumi S, Yagi Y, Sakai A, Shiomi H, Masuda A, Okaya S, Kutsumi H, Yoshida M and Honda K. Serum apolipoprotein A2 isoforms in autoimmune pancreatitis. Biochem Biophys Res Commun, 2018. 497(3): 903-907. PMID: 29481802 DOI: 10.1016/j.bbrc.2018.02.170
  3. Sekikawa S, Onda T, Miura N, Nomura T, Takano N, Shibahara T and Honda K. Underexpression of alpha-1-microglobulin/bikunin precursor predicts a poor prognosis in oral squamous cell carcinoma. Int J Oncol, 2018. 53(6): 2605-2614. PMID: 30272341 DOI: 10.3892/ijo.2018.4581
  4. Shoji H, Miura N, Ueno H and Honda K. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Pancreatology, 2018. 18(6): 624-629. PMID: 29921500 DOI: 10.1016/j.pan.2018.06.003

2017

  1. Hirata Y, Kobayashi T, Nishiumi S, Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Yamada T, Honda K, Azuma T and Yoshida M. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clin Chim Acta, 2017. 468: 98-104. PMID: 28215548 DOI: 10.1016/j.cca.2017.02.011
  2. Kakuya T, Mori T, Yoshimoto S, Watabe Y, Miura N, Shoji H, Onidani K, Shibahara T and Honda K. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. Int J Oral Maxillofac Surg, 2017. 46(8): 968-976. PMID: 8385383 DOI: 10.1016/j.ijom.2017.03.001
  3. Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe SI, Noro R, Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y and Honda K. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomark Med, 2017. 11(9); 721-731. PMID: 28658966 DOI: 10.2217/bmm-2017-0150
  4. Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y and Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget, 2017. 8(56): 95083-95094. PMID: 28611302 PMCID: PMC5707007 DOI: 10.18632/oncotarget.18297
  5. Yamaguchi H, Ito Y, Miura N, Nagamura Y, Nakabo A, Fukami K, Honda K and Sakai R. Actinin-1 and actinin-4 play essential but distinct roles in invadopodia formation by carcinoma cells. Eur J Cell Biol, 2017. 96(7): 685-694. PMID: 28797528 DOI: 10.1016/j.ejcb.2017.07.005

2016

  1. Honda K and Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomarkers in Medicine, 2016. 10(11): 1197-1207. PMID: 27673558 PMCID: PMC5493967 DOI: 10.2217/bmm-2016-0209
  2. Miura N, Kamita M, Kakuya T, Fujiwara Y, Tsuta K, Shiraishi H, Takeshita F, Ochiya T, Shoji H, Huang W, Ohe Y, Yamada T and Honda K. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget, 2016. 7(22): 33165-33178. PMID: 27121206 PMCID: PMC5078083 DOI: 10.18632/oncotarget.8890
  3. Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T and Yamada Y. A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Cancer Chemotherapy and Pharmacology, 2016. 78(3): 567-575. PMID: 27438067 DOI: 10.1007/s00280-016-3111-x
  4. Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M and Terasaki T. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. Plos One, 2016. 11(8). e0161009 PMID: 27579675 PMCID: PMC5007017 DOI: 10.1371/journal.pone.0161009

2015

  1. Honda K. The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer. Cell Biosci, 2015. 5: 41. PMID: 26288717 PMCID: PMC4539665 DOI: 10.1186/s13578-015-0031-0
  2. Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S and Yamada T. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep, 2015. 5: 15921. PMID: 26549697 PMCID: PMC4637825 DOI: 10.1038/srep15921
  3. Okamoto N, Suzuki H, Kawahara K, Honda K, Miura N, Hirashima T, Tamiya M, Morishita N, Shiroyama T, Tanaka A, Tani E, Hamaguchi M, Kitani M, Yamada T and Kawase I. The Alternatively Spliced Actinin-4 Variant as a Prognostic Marker for Metastasis in Small-cell Lung Cancer. Anticancer Research, 2015. 35(3): 1663-1667. PMID:25750325
  4. Watanabe T, Ueno H, Watabe Y, Hiraoka N, Morizane C, Itami J, Okusaka T, Miura N, Kakizaki T, Kakuya T, Kamita M, Tsuchida A, Nagakawa Y, Wilber H, Yamada T and Honda K. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. British Journal of Cancer, 2015. 112(4): 704-713. PMID: 25602965 PMCID: PMC4333489 DOI: 10.1038/bjc.2014.623

2014

  1. Fukushima S, Yoshida A, Honda K, Maeshima AM, Narita Y, Yamada T, Shibui S and Tsuda H. Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation. Brain Tumor Pathol, 2014. 31(1): 11-16. PMID: 23504125 DOI: 10.1007/s10014-013-0139-z
  2. Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, Morioka H, Toyama Y and Yamada T. MicroRNA expression and functional profiles of osteosarcoma. Oncology, 2014. 86(2): 94-103. PMID: 24457375 DOI: 10.1159/000357408
  3. Masuda M, Chen WY, Miyanaga A, Nakamura Y, Kawasaki K, Sakuma T, Ono M, Chen CL, Honda K and Yamada T. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteomics, 2014. 13(6): 1429-1438. PMID: 24643969 PMCID: PMC4047464 DOI: 10.1074/mcp.M113.033845
  4. Tanaka N, Yamashita T, Yamamoto S, Matsunobu T, Tsuda H, Honda K, Yamada T, Tamai S and Shiotani A. Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer. Anticancer Res, 2014. 34(6): 3157-3163. PMID: 24922688
  5. Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T and Honda K. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Medicine, 2014. 3(3): 613-622. PMID: 24574362 PMCID: PMC4101752 DOI: 10.1002/cam4.214

2013

  1. Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N and Yamada T. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol, 2013. 43(2): 103-109. PMID: 23248327 DOI: 10.1093/jjco/hys200
  2. Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, Igaki H, Ito Y, Hoshino S, Tachibana S, Watanabe T, Furuta K, Sekine S, Umaki T, Watabe Y, Miura N, Ono M, Tsuchida A and Yamada T. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci, 2013. 104(8): 1045-1051. PMID: 23648090 DOI: 10.1111/cas.12187
  3. Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, Miyamoto A, Shinagawa S, Miura N, Tsuda H, Sakuma T, Asamura H, Gemma A and Yamada T. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol, 2013. 24(1): 84-90. PMID: 22887464 DOI: 10.1093/annonc/mds215
  4. Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K and Yamada T. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann Oncol, 2013. 24(10): 2594-2600. PMID: 23899839 DOI: 10.1093/annonc/mdt293
  5. Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, Watabe Y, Honda K, Yamada T, Yoshimoto S, Asai M, Okano H, Kanai Y and Tsuda H. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol, 2013. 26(8): 1041-1050. PMID: 23558573 DOI: 10.1038/modpathol.2013.54

2012

  1. Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, Ioka T, Tsuchida A, Shimahara T, Shimahara M, Yasunami Y, Kuwabara H, Sakuma T, Otsuka Y, Ota N, Shitashige M, Kosuge T, Buchler MW and Yamada T. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One, 2012. 7(10): e46908. PMID: 23056525 PMCID: PMC3466211 DOI: 10.1371/journal.pone.0046908
  2. Ono M, Kamita M, Murakoshi Y, Matsubara J, Honda K, Miho B, Sakuma T and Yamada T. Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry. Int J Proteomics, 2012. 2012: 897412. PMID: 22844596 PMCID: PMC3400370 DOI: 10.1155/2012/897412
  3. Sakane A, Abdallah AA, Nakano K, Honda K, Ikeda W, Nishikawa Y, Matsumoto M, Matsushita N, Kitamura T and Sasaki T. Rab13 small G protein and junctional Rab13-binding protein (JRAB) orchestrate actin cytoskeletal organization during epithelial junctional development. J Biol Chem, 2012. 287(51): 42455-42468. PMID: 23100251 PMCID: PMC3522248 DOI: 10.1074/jbc.M112.383653
  4. Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I and Yamada T. beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology, 2012. 142(3): 572-581. PMID: 22155184 DOI: 10.1053/j.gastro.2011.11.041
  5. Takakura M, Yokomizo A, Tanaka Y, Kobayashi M, Jung G, Banno M, Sakuma T, Imada K, Oda Y, Kamita M, Honda K, Yamada T, Naito S and Ono M. Carbonic anhydrase I as a new plasma biomarker for prostate cancer. ISRN Oncol, 2012. 2012: 768190. PMID: 23213568 PMCID: PMC3506895 DOI: 10.5402月20日12/768190
  6. Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T and Matsubara O. ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology, 2012. 60(7): 1073-1083. PMID: 22348389 DOI: 10.1111/j.1365-2559.2011.04163.x

2011

  1. Ito H, Honda K, Satow R, Arai E, Shitashige M, Ono M, Sakuma T, Sakano S, Naito K, Matsuyama H and Yamada T. Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney. Jpn J Clin Oncol, 2011. 41(7): 847-853. PMID: 21576114 DOI: 10.1093/jjco/hyr060
  2. Matsubara J, Honda K, Ono M, Sekine S, Tanaka Y, Kobayashi M, Jung G, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T and Yamada T. Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol Biomarkers Prev, 2011. 20(10): 2195-2203. PMID: 21828233 DOI: 10.1158/1055-9965.EPI-11-0400
  3. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S and Yamada T. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 2011. 20(1): 160-171. PMID: 21148121 DOI: 10.1158/1055-9965.EPI-10-0397
  4. Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, Sakuma T, Kuwabara H, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Shimahara M, Yasunami Y, Ino Y, Tsuchida A, Aoki T, Tsugane S and Yamada T. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci, 2011. 102(3): 630-638. PMID: 21199170 DOI: 10.1111/j.1349-7006.2010.01818.x
  5. Yokomizo A, Takakura M, Kanai Y, Sakuma T, Matsubara J, Honda K, Naito S, Yamada T and Ono M. Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney. Cancer Biomark, 2011. 10(3-4): 175-183. PMID: 22674303 DOI: 10.3233/CBM-2012-0243

2010

  1. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A and Yamada T. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther, 2010. 9(3): 535-544. PMID: 20159990 DOI: 10.1158/1535-7163.MCT-09-0774
  2. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S and Yamada T. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics, 2010. 9(4): 695-704. PMID:20061307 PMCID: PMC2860233 DOI: 10.1074/mcp.M900234-MCP200
  3. Sakane A, Honda K and Sasaki T. Rab13 regulates neurite outgrowth in PC12 cells through its effector protein, JRAB/MICAL-L2. Mol Cell Biol, 2010. 30(4): 1077-1087. PMID: 20008558 PMCID: PMC2815571 DOI: 10.1128/MCB.01067-09
  4. Satow R, Shitashige M, Jigami T, Honda K, Ono M, Hirohashi S and Yamada T. Traf2- and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation. J Biol Chem, 2010. 285(34): 26289-26294. PMID: 20566648 PMCID: PMC2924048 DOI: 10.1074/jbc.M109.090597
  5. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S and Yamada T. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res, 2010. 16(9): 2518-2528. PMID: 20388846 DOI: 10.1158/1078-0432.CCR-09-2214
  6. Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T, Ono M, Hirohashi S and Yamada T. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res, 2010. 70(12): 5024-5033. PMID: 20530691 DOI: 10.1158/0008-5472.CAN-10-0306

2009

  1. Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S and Yamada T. Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol, 2009. 27(13): 2261-2268. PMID: 19289617 DOI: 10.1200/JCO.2008.19.9745
  2. Negishi A, Masuda M, Ono M, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai Y, Omura K, Hirohashi S and Yamada T. Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma. Cancer Sci, 2009. 100(9): 1605-1611. PMID: 19522851 DOI: 10.1111/j.1349-7006.2009.01227.x
  3. Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Omura K, Hirohashi S and Yamada T. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci, 2009. 100(3): 514-519. PMID: 19154406 DOI: 10.1111/j.1349-7006.2008.01055.x
  4. Ono M, Matsubara J, Honda K, Sakuma T, Hashiguchi T, Nose H, Nakamori S, Okusaka T, Kosuge T, Sata N, Nagai H, Ioka T, Tanaka S, Tsuchida A, Aoki T, Shimahara M, Yasunami Y, Itoi T, Moriyasu F, Negishi A, Kuwabara H, Shoji A, Hirohashi S and Yamada T. Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. J Biol Chem, 2009. 284(42): 29041-29049. PMID: 19696023 PMCID: PMC2781450 DOI: 10.1074/jbc.M109.041749
  5. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S and Yamada T. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci, 2009. 100(12): 2268-2274. PMID: 19725836 DOI: 10.1111/j.1349-7006.2009.01310.x
  6. Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T and Matsubara O. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol, 2009. 22(4): 499-507. PMID: 19151661 DOI: 10.1038/modpathol.2008.234

2008

  1. Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, Umaki T, Onozato K, Shitashige M, Yamaguchi U, Ono M, Tsuchida A, Aoki T, Inazawa J, Hirohashi S and Yamada T. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res, 2008. 14(17): 5348-5356. PMID: 18765526 DOI: 10.1158/1078-0432.CCR-08-0075
  2. Shitashige M, Satow R, Honda K, Ono M, Hirohashi S and Yamada T. Regulation of Wnt signaling by the nuclear pore complex. Gastroenterology, 2008. 134(7): 1961-1971, 1971 e1961-1964. PMID: 18439914 DOI: 10.1053/j.gastro.2008.03.010
  3. Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H, Shimada Y, Sasako M, Shimoda T, Kawai A, Hirohashi S and Yamada T. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol, 2008. 26(25): 4100-4108. PMID: 18757323 DOI: 10.1200/JCO.2007.14.2331

2007

  1. Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, Hirohashi S and Yamada T. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics, 2007. 6(3): 479-491. PMID: 17151021 DOI: 10.1074/mcp.M600129-MCP200
  2. Huang L, Shitashige M, Satow R, Honda K, Ono M, Yun J, Tomida A, Tsuruo T, Hirohashi S and Yamada T. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology, 2007. 133(5): 1569-1578. PMID: 17983804 DOI: 10.1053/j.gastro.2007.08.011
  3. Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y, Imai K, Hirohashi S and Yamada T. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res, 2007. 67(3): 911-918. PMID: 17283121 DOI: 10.1158/0008-5472.CAN-06-2360
  4. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Yamada T, Kato H, Nishimura T, Todo S and Hirohashi S. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci, 2007. 852(1-2): 257-267. PMID: 17303479 DOI: 10.1016/j.jchromb.2007.01.029
  5. Kikuchi S, Honda K, Handa Y, Kato H, Yamashita K, Umaki T, Shitashige M, Ono M, Tsuchida A, Aoki T, Hirohashi S and Yamada T. Serum albumin-associated peptides of patients with uterine endometrial cancer. Cancer Sci, 2007. 98(6): 822-829. PMID: 17419710 DOI: 10.1111/j.1349-7006.2007.00458.x
  6. Ota Y, Takagi Y, Osaka Y, Shinohara M, Hoshino S, Tsuchida A, Aoki T, Honda K and Yamada T. Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer. Oncol Rep, 2007. 18(3): 653-657. PMID: 17671715
  7. Shitashige M, Naishiro Y, Idogawa M, Honda K, Ono M, Hirohashi S and Yamada T. Involvement of splicing factor-1 in beta-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology, 2007. 132(3): 1039-1054. PMID: 17383426 DOI: 10.1053/j.gastro.2007.01.007
  8. Shitashige M, Satow R, Honda K, Ono M, Hirohashi S and Yamada T. Increased susceptibility of Sf1(+/-) mice to azoxymethane-induced colon tumorigenesis. Cancer Sci, 2007. 98(12): 1862-1867. PMID: 17900258 DOI: 10.1111/j.1349-7006.2007.00629.x
  9. Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T and Matsubara O. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol, 2007. 20(12): 1278-1285. PMID: 17873890 DOI: 10.1038/modpathol.3800966

2006

  1. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, Hirohashi S and Yamada T. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics, 2006. 5(7): 1338-1347. PMID: 16552026 DOI: 10.1074/mcp.T500039-MCP200

2005

  1. Hara T, Honda K, Ono M, Naito K, Hirohashi S and Yamada T. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol, 2005. 174(4 Pt 1): 1213-1217. PMID: 16145372
  2. Hayashida Y, Honda K, Idogawa M, Ino Y, Ono M, Tsuchida A, Aoki T, Hirohashi S and Yamada T. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res, 2005. 65(19): 8836-8845. PMID: 16204054 DOI: 10.1158/0008-5472.CAN-05-0718
  3. Hayashida Y, Honda K, Osaka Y, Hara T, Umaki T, Tsuchida A, Aoki T, Hirohashi S and Yamada T. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res, 2005. 11(22): 8042-8047. PMID: 16299234 DOI: 10.1158/1078-0432.CCR-05-0656
  4. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Hirohashi S and Yamada T. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res, 2005. 65(22): 10613-10622. PMID: 16288055 DOI: 10.1158/0008-5472.CAN-05-1851
  5. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, Ino Y, Ono M and Hirohashi S. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology, 2005. 128(1): 51-62. PMID: 15633123
  6. Idogawa M, Yamada T, Honda K, Sato S, Imai K and Hirohashi S. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology, 2005. 128(7): 1919-1936. PMID: 15940627
  7. Naishiro Y, Yamada T, Idogawa M, Honda K, Takada M, Kondo T, Imai K and Hirohashi S. Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein. Oncogene, 2005. 24(19): 3141-3153. PMID: 15735679 DOI:10.1038/sj.onc.1208517
  8. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M and Hirohashi S. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res, 2005. 11(7): 2531-2539. PMID: 15814630 DOI: 10.1158/1078-0432.CCR-04-0866
  9. Sato S, Idogawa M, Honda K, Fujii G, Kawashima H, Takekuma K, Hoshika A, Hirohashi S and Yamada T. Beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. Gastroenterology, 2005. 129(4): 1225-1236. PMID: 16230076 DOI: 10.1053/j.gastro.2005.07.025